Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective CGM study of switching from insulin glargine 100 U/ml to insulin glargine 300 U/ml in type 2 diabetes with renal impairment
2021-005353-82Phase 4Active
- Sponsor
- Sanofi
- Start
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of insulin glargine in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Primary endpoint: Change in Time in Range. Started Feb 2022; status: active.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2021-005353-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005353-82.